 |
 |
 |
|
Market Protection Licensing Strategies for Pharmaceutical- and Biotech Companies
This workshop provides an overview of the market protection and licensing strategies available for pharmaceutical and biotech-nology companies. The market protection strategies will include information on how to obtain, exploit and defend rights that result from patents, data protection, and other exclusivities. Licensing strategies will focus on effective approaches for protecting intellectual property and other assets in the drug development process. The course will also include U.S. and European perspectives on licensing from research institutes.
Participants will have the opportunity for interaction over case studies and during question and answer session.
Manuel Kunst, PhD, Biochemist, worked in the patent and trademark department of Ciba-Geigy/Novartis from 1990 to 1999, since 2000 private practice with Maucher, Börjes & Kollegen in Freiburg, Germany. He is both European and German patent attorney, specialised in the area of chemistry, pharma and biotechnology.
Marc A. Rubenstein is a partner in Ropes & Gray’s Corporate Department, Boston, USA, and a member of the firm’s Life Science and Intellectual Property & Technology Practices. His corporate practice is focused on representing clients in the life sciences industry, including companies in the biotechnology, medical device an e-health industries in the US and Europe. He has got a B.A. from Cornell University and earned a J.D. from Cornell Law School.
Gregory J. Glover, Greg, a partner in the Washington, D.C. office of Ropes & Gray, is a licensed physician (A.B. in Biochemical Sciences from Harvard College) and registered patent attorney (J.D. from Harvard Law School) with experience in food and drug law, intellectual property law, and technology licensing.
Marc Reinhardt, Cap Gemini Ernst & Young, Stuttgart, Germany, is Principal in the Global Life Sciences Sector and Head of the Biotech Consulting Team of Cap Gemini Ernst & Young, Central Europe. In this function he has advised entrepreneurial Biotech firms as well as mature businesses and public institutions in many large and small projects. He has over 9 years of experience consulting companies in the areas of Strategy/Organisation, Know- ledge Management and Supply Chain Management. He studied Business Administration in Stuttgart, Los Angeles and Paris.
Gabriele Alt joined the European Patent Office, Munich, Germany, in 1990 and worked first as a substantive and search examiner in the field of biotechnology. Now she is a member of a board of appeal at the European Patent Office dealing with biotechnology cases. She has a diploma in biology and studied molecular biology at the Friedrich-Alexander-University, Erlangen-Nürnberg, Germany and at the Institute de Biologie Moléculaire et Cellulaire du CNRS at Straßbourg.
Bernhard Hertel, PhD, CEO, Garching Innovation GmbH, Munich, Germany studied physics at the Technical Universities of Stuttgart and Berlin. After 10 years at the Max-Planck-Institute for Metal Research he is with Garching Innovation (GI), the technology transfer agency of the Max-Planck-Society since 1979. Since then he was responsible for projects related to materials science, software and all types of scientific and medical instrumentation. In 1999 he was appointed as a managing director of GI.
Marc Reinhardt (Cap Gemini Ernst & Young)
Gabriele Alt (European Patent Office)
Patent protection, data protection, orphan drug exclusivity, know-how, trade secrets, industry the role of research and development and licensing agreement. (European focus)
Manuel Kunst (Maucher, Börjes & Kollegen) with commentary by Marc Rubenstein (Ropes & Gray's) and Gregory Glover (Ropes & Gray)
Gregory Glover (Ropes & Gray) and Marc Rubenstein (Ropes & Gray) with commentary by Manuel Kunst (Maucher, Börjes & Kollegen)
Biotech-Pharma licensing, structuring later stage deals, bankruptcy
Marc Rubenstein (Ropes & Gray) and Manuel Kunst (Maucher, Börjes & Kollegen)
European and U.S. Perspectives
Bernhard Hertel (Garching Innovation GmbH)
Strategies in market protection and licensing
Manuel Kunst (Maucher, Börjes & Kollegen), Marc Rubenstein (Ropes & Gray) and Gregory Glover (Ropes & Gray)
Discussion
OVERVIEW
COURSE
1
COURSE
3